NAT, 50-fold, sterile
It is used as an additive to nutrient media when it is necessary to differentiate hybridoma cells for production of monoclonal antibodies.
To obtain hybridoma producing the necessary monoclonal antibodies, a laboratory animal is immunized with certain antigen for 1-2 months. After immunization, lymphocytes are isolated from the spleen. To obtain an "immortal" cell line, these lymphocytes are fused with myeloma cells devoid of the GGFT enzyme (such cells are sensitive to the NAT selective agent (hypoxanthine, aminopterin, thymidine)).
The cells obtained after fusion are incubated in the presence of NAT for 10-14 days. In this case, myeloma cells in the presence of aminopterin lose their ability to synthesize nucleotides and die. Lymphocytes and successfully fused hybridoma cells survive, because they can use hypoxanthine. Over time, the lymphocytes in the culture die and only the "immortal" hybridoma cells remain.
This product is intended for research purposes.
Contains: hypoxanthine - 5 mM, aminopterin - 20 mM, thymidine - 0.8 mM
The preparation is diluted in 10 ml of distilled water.
